Quest Diagnostics announced its financial results for the quarter and full year ended December 31, 2025, alongside new capital return initiatives. The company's Board authorized an additional $1 billion for its common stock repurchase program and increased the quarterly dividend by 7.5%, from $0.80 to $0.86 per share.
